CompletedPhase 4

Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity

Started 2005-02

Plain-language summary

The aim of this study is to investigate whether the pharmacokinetics of atorvastatin and/or its metabolites is altered in patients with confirmed atorvastatin-induced myopathy compared to healthy controls.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * above 18 years * previous history of atorvastatin-associated myotoxicity Exclusion Criteria: * current treatment with drugs or herbal remedies with known pharmacokinetic interaction potential with atorvastatin * previous CK levels above ten times the upper limit of normal range * pregnancy and persistent muscular complaints after a four week wash-out period of statin treatment

What they're measuring

Statin toxicity

Timeframe: 1 year

Trial details

NCT IDNCT00120055

SponsorUniversity of Oslo School of Pharmacy

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Myopathy trials